Pirfenidone attenuates cardiac hypertrophy against isoproterenol by inhibiting activation of the janus tyrosine kinase-2/signal transducer and activator of transcription 3 (JAK-2/STAT3) signaling pathway
Article in Bioengineered (May 2022)
The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.
Article in Bioengineered (May 2022)
Article in BioDrugs (September 2020)
Article in Medical Hypotheses (June 2020)